{
    "hands_on_practices": [
        {
            "introduction": "The pathophysiology of peptic ulcer disease is fundamentally a story of imbalance between aggressive factors, like gastric acid, and defensive mechanisms, such as duodenal bicarbonate secretion. This exercise challenges you to move beyond qualitative descriptions and apply a quantitative model to this balance. By calculating the residual acidity in the duodenal lumen under specific physiological conditions, you will gain a concrete understanding of the harsh environment that can lead to mucosal injury and ulceration. ",
            "id": "4655988",
            "problem": "A patient with recurrent bleeding from a duodenal ulcer is evaluated to quantify the residual acidity at the duodenal mucosa under a steady-state postprandial condition. In this state, hydrogen ion equivalents delivered from the stomach into the duodenum and bicarbonate equivalents secreted into the duodenum from the pancreas and Brunner’s glands are assumed to interact via complete acid–base neutralization, with one bicarbonate neutralizing one hydrogen ion. The duodenal lumen is modeled as a well-mixed compartment with constant volumetric flow, and hydrogen ion activity is approximated by molar concentration under dilute conditions. The acid delivery rate into the duodenum is measured as $A = 1.25 \\ \\mathrm{mmol}/\\mathrm{min}$. The combined bicarbonate secretion rate into the duodenum is $B = 0.95 \\ \\mathrm{mmol}/\\mathrm{min}$. The duodenal volumetric flow is $Q = 0.12 \\ \\mathrm{L}/\\mathrm{min}$. Under these assumptions and ignoring other buffering species, compute the residual acidity at the duodenal mucosa as the hydrogen ion concentration represented by the acidity scale defined by the negative base-$10$ logarithm of hydrogen ion activity. Express the final acidity as the pH of the duodenal fluid. Round your answer to four significant figures and report it as a dimensionless number.",
            "solution": "The pathophysiological setting involves the balance between gastric hydrogen ion delivery and duodenal neutralization by bicarbonate. The fundamental basis for the calculation is the acid–base neutralization reaction\n$$\\mathrm{H}^{+} + \\mathrm{HCO}_{3}^{-} \\rightarrow \\mathrm{CO}_{2} + \\mathrm{H}_{2}\\mathrm{O},$$\nwhich is $1{:}1$ in stoichiometry. Let the hydrogen ion delivery rate be $A$ and the bicarbonate secretion rate be $B$, both in $\\mathrm{mmol}/\\mathrm{min}$. The net residual hydrogen ion flux into the duodenal lumen is\n$$J_{\\mathrm{H}} = A - B.$$\nGiven $A = 1.25 \\ \\mathrm{mmol}/\\mathrm{min}$ and $B = 0.95 \\ \\mathrm{mmol}/\\mathrm{min}$, we obtain\n$$J_{\\mathrm{H}} = 1.25 - 0.95 = 0.30 \\ \\mathrm{mmol}/\\mathrm{min}.$$\nAssuming a well-mixed duodenal compartment with volumetric flow $Q = 0.12 \\ \\mathrm{L}/\\mathrm{min}$, the steady-state hydrogen ion concentration in the lumen (before activity correction, which is taken as unity for dilute solutions) is the net flux divided by the volumetric flow:\n$$[\\mathrm{H}^{+}]_{\\mathrm{mmol/L}} = \\frac{J_{\\mathrm{H}}}{Q} = \\frac{0.30 \\ \\mathrm{mmol}/\\mathrm{min}}{0.12 \\ \\mathrm{L}/\\mathrm{min}} = 2.5 \\ \\mathrm{mmol}/\\mathrm{L}.$$\nConvert this to $\\mathrm{mol}/\\mathrm{L}$:\n$$[\\mathrm{H}^{+}]_{\\mathrm{M}} = 2.5 \\ \\mathrm{mmol}/\\mathrm{L} \\times \\frac{1 \\ \\mathrm{mol}}{1000 \\ \\mathrm{mmol}} = 0.0025 \\ \\mathrm{mol}/\\mathrm{L}.$$\nBy definition, the acidity scale pH is the negative base-$10$ logarithm of the hydrogen ion activity. Under the assumption that activity $\\approx$ concentration in this dilute regime (activity coefficient $\\gamma \\approx 1$), we use\n$$\\mathrm{pH} = -\\log_{10}\\!\\left([\\mathrm{H}^{+}]_{\\mathrm{M}}\\right) = -\\log_{10}(0.0025).$$\nCompute the logarithm:\n$$\\log_{10}(0.0025) = \\log_{10}(2.5 \\times 10^{-3}) = \\log_{10}(2.5) - 3.$$\nUsing $\\log_{10}(2.5) \\approx 0.39794$, we get\n$$\\log_{10}(0.0025) \\approx 0.39794 - 3 = -2.60206.$$\nTherefore,\n$$\\mathrm{pH} \\approx -(-2.60206) = 2.60206.$$\nRounded to four significant figures, the residual duodenal pH is $2.602$. From a pathophysiological perspective, sustained luminal $\\mathrm{pH}$ in the range below $3$ increases the risk of mucosal injury, consistent with duodenal ulcer complications; however, the requested output is the calculated pH value under the specified steady-state assumptions.",
            "answer": "$$\\boxed{2.602}$$"
        },
        {
            "introduction": "Accurate diagnosis of Helicobacter pylori infection is a cornerstone of modern peptic ulcer management, as eradication therapy is curative for many patients. However, clinical practice is often complicated by the fact that medications used to treat symptoms, such as Proton Pump Inhibitors (PPIs), can interfere with the diagnostic tests themselves. This problem delves into the biophysical and microbiological reasons for these test failures, requiring you to analyze how changes in gastric pH and bacterial load affect the enzymatic assays used for diagnosis. ",
            "id": "4656047",
            "problem": "A $52$-year-old man with epigastric pain is evaluated for suspected peptic ulcer disease. Four weeks ago ($4$ weeks), he began self-medication with a proton pump inhibitor (PPI) and completed a $7$-day course of a macrolide antibiotic for sinusitis one week ago. He now undergoes both a Urea Breath Test (UBT) using carbon-$13$-labeled urea and a Rapid Urease Test (RUT) on an antral biopsy; both return negative. Two months earlier, before these medications, a stool antigen test was positive for Helicobacter pylori (H. pylori). The endoscopist asks whether the medications could plausibly have caused false negatives.\n\nUsing first principles about enzyme kinetics and bacterial population dynamics, consider the following model. The rate of labeled carbon dioxide production in the UBT is proportional to H. pylori urease activity across the gastric mucosa, which for a given local substrate concentration $[S]$ (urea) follows the Michaelis–Menten relation:\n$$\nv = \\frac{k_{\\mathrm{cat}} E_{\\mathrm{total}} [S]}{K_m + [S]} ,\n$$\nwhere $k_{\\mathrm{cat}}$ is the catalytic turnover number, $E_{\\mathrm{total}}$ is the total urease enzyme concentration available in the stomach, and $K_m$ is the Michaelis constant. The test yields a positive result if the integrated production rate exceeds a detection threshold $T_{\\mathrm{UBT}}$. For the biopsy-based RUT, positivity requires that the local urease activity within the sampled antral tissue exceeds a threshold $T_{\\mathrm{RUT}}$.\n\nAssume that the total urease capacity satisfies $E_{\\mathrm{total}} \\propto n \\cdot e(pH)$, where $n$ is the H. pylori bacterial density in the relevant mucosal region and $e(pH)$ captures the pH-dependent expression level of urease per bacterium. Empirically, acid stress upregulates urease gene expression, so $e(pH)$ decreases as luminal $pH$ rises toward neutrality, even if the catalytic efficiency $k_{\\mathrm{cat}}$ of urease itself has a near-neutral optimum. Also assume that antibiotics reduce $n$ by a factor that depends on their bacteriostatic or bactericidal effects, while PPIs both raise gastric $pH$ (for example from $pH \\approx 1.5$ to $pH \\approx 4$) and can redistribute H. pylori colonization from the antrum to the corpus, thereby altering local $n$ in the sampled site.\n\nWhich of the following mechanisms most plausibly explain the observed false-negative UBT and RUT in this patient under the above first-principles framework?\n\nA. Antibiotic exposure reduces the H. pylori bacterial density $n$, lowering $E_{\\mathrm{total}}$ and the integrated urease activity below $T_{\\mathrm{UBT}}$ and $T_{\\mathrm{RUT}}$.\n\nB. PPIs increase gastric acidity (lower $pH$), directly denaturing urease and reducing $k_{\\mathrm{cat}}$ in vivo, thereby causing test negativity.\n\nC. By raising gastric $pH$, PPIs downregulate urease gene expression per bacterium, decreasing $e(pH)$ and thus $E_{\\mathrm{total}}$ despite catalytic activity being optimal near neutrality, leading to subthreshold urease activity.\n\nD. PPIs shift H. pylori colonization proximally toward the corpus, reducing antral $n$ below the RUT sampling threshold and biasing the antral biopsy toward a false negative without excluding corpus colonization.\n\nE. Antibiotics cause permanent covalent inactivation of urease active sites that persists in the gastric mucosa long after bacterial clearance, diminishing $E_{\\mathrm{total}}$ independently of $n$ and $e(pH)$.",
            "solution": "The objective is to identify the plausible mechanisms that could lead to false-negative results for both the Urea Breath Test (UBT) and the Rapid Urease Test (RUT). A false-negative result means the total or local urease activity, $v$, has fallen below the respective detection thresholds, $T_{\\mathrm{UBT}}$ and $T_{\\mathrm{RUT}}$. According to the provided model, the urease activity $v$ is a function of total enzyme concentration $E_{\\mathrm{total}}$ and its catalytic efficiency $k_{\\mathrm{cat}}$:\n$$v = \\frac{k_{\\mathrm{cat}} E_{\\mathrm{total}} [S]}{K_m + [S]}$$\nA decrease in $v$ must stem from a decrease in $k_{\\mathrm{cat}}$ or $E_{\\mathrm{total}}$ (as $[S]$ is exogenously supplied). Furthermore, the total enzyme concentration is given by $E_{\\mathrm{total}} \\propto n \\cdot e(pH)$. Therefore, a drop in activity $v$ can be caused by:\n1.  A decrease in bacterial density, $n$.\n2.  A decrease in urease expression per bacterium, $e(pH)$.\n3.  A decrease in the catalytic turnover number, $k_{\\mathrm{cat}}$.\n\nWe will now analyze the effects of the patient's medications in this context and evaluate each option.\n\n**A. Antibiotic exposure reduces the H. pylori bacterial density $n$, lowering $E_{\\mathrm{total}}$ and the integrated urease activity below $T_{\\mathrm{UBT}}$ and $T_{\\mathrm{RUT}}$.**\n*   **Analysis:** The problem statement explicitly assumes that \"antibiotics reduce $n$\". A macrolide antibiotic, even if given for sinusitis, has systemic effects and is known to be active against *H. pylori*. The patient completed the course only one week prior to testing. A reduction in bacterial density ($n$) directly reduces the total enzyme concentration ($E_{\\mathrm{total}} \\propto n \\cdot e(pH)$) throughout the stomach. This reduction in $E_{\\mathrm{total}}$ would lead to a lower overall urease activity $v$, which could plausibly fall below the detection thresholds for both the whole-stomach UBT and the local-sample RUT. This is a primary and well-established reason for false-negative urease-based tests.\n*   **Verdict:** **Correct**.\n\n**B. PPIs increase gastric acidity (lower $pH$), directly denaturing urease and reducing $k_{\\mathrm{cat}}$ in vivo, thereby causing test negativity.**\n*   **Analysis:** This statement contains a fundamental contradiction. Proton pump inhibitors (PPIs) work by inhibiting the H+/K+ ATPase pump in gastric parietal cells, which *decreases* acid secretion. Consequently, PPIs *decrease* gastric acidity, which means they *raise* the gastric $pH$. The problem statement explicitly supports this, giving an example of a $pH$ rise from $\\approx 1.5$ to $\\approx 4$. The premise of this option is factually incorrect, rendering the subsequent reasoning invalid.\n*   **Verdict:** **Incorrect**.\n\n**C. By raising gastric $pH$, PPIs downregulate urease gene expression per bacterium, decreasing $e(pH)$ and thus $E_{\\mathrm{total}}$ despite catalytic activity being optimal near neutrality, leading to subthreshold urease activity.**\n*   **Analysis:** This mechanism is consistent with the model's assumptions. The problem states that PPIs raise gastric $pH$. It also states that *H. pylori* upregulates urease expression ($e(pH)$) in response to acid stress, so $e(pH)$ *decreases* as the $pH$ rises toward neutrality. A decrease in $e(pH)$ leads to a decrease in the total amount of enzyme, $E_{\\mathrm{total}}$, since $E_{\\mathrm{total}} \\propto n \\cdot e(pH)$. This reduction in $E_{\\mathrm{total}}$ would lower the overall reaction rate $v$, potentially causing both UBT and RUT to be negative. The statement correctly distinguishes this effect on enzyme *expression* from the effect on enzyme *activity* ($k_{\\mathrm{cat}}$), which is optimal at a higher pH. The patient's $4$-week use of a PPI is sufficient for this physiological adaptation to occur.\n*   **Verdict:** **Correct**.\n\n**D. PPIs shift H. pylori colonization proximally toward the corpus, reducing antral $n$ below the RUT sampling threshold and biasing the antral biopsy toward a false negative without excluding corpus colonization.**\n*   **Analysis:** This mechanism is also explicitly described in the problem's assumptions. Long-term PPI use can alter the gastric environment, favoring *H. pylori* growth in the corpus over the antrum. The RUT was performed on an *antral biopsy*. A significant reduction in the local bacterial density ($n$) in the antrum could cause the local urease activity to fall below the $T_{\\mathrm{RUT}}$ threshold, yielding a false-negative RUT. This is a well-known cause of sampling error in endoscopy. While this directly explains the RUT result, a significant redistribution and potential overall decrease in bacterial load could also contribute to a negative UBT. This is a plausible mechanism based on the given information.\n*   **Verdict:** **Correct**.\n\n**E. Antibiotics cause permanent covalent inactivation of urease active sites that persists in the gastric mucosa long after bacterial clearance, diminishing $E_{\\mathrm{total}}$ independently of $n$ and $e(pH)$.**\n*   **Analysis:** This option proposes a mechanism that is both biologically implausible and inconsistent with the provided model. First, macrolide antibiotics typically inhibit bacterial protein synthesis; they are not known to be covalent inactivators of enzymes like urease. Second, the idea of inactivated enzyme \"persisting\" in the mucosa independently of the bacteria is incorrect; enzymes are proteins with a finite lifespan and would be degraded or shed along with the mucosal lining. Most importantly, the claim that this mechanism diminishes $E_{\\mathrm{total}}$ \"independently of $n$ and $e(pH)$\" directly contradicts the model's fundamental assumption that $E_{\\mathrm{total}} \\propto n \\cdot e(pH)$. If the bacteria are absent ($n \\to 0$), then $E_{\\mathrm{total}}$ must also approach $0$.\n*   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{ACD}$$"
        },
        {
            "introduction": "Managing a patient with a bleeding peptic ulcer often involves navigating complex, competing risks, especially in the setting of critical comorbidities. This scenario places you at the intersection of gastroenterology, cardiology, and pharmacology, forcing a decision on PPI therapy for a patient who also requires clopidogrel after coronary stenting. To arrive at the best clinical judgment, you must precisely separate the local, pH-dependent benefits of acid suppression at the ulcer base from the systemic, metabolic drug interactions occurring in the liver. ",
            "id": "4656029",
            "problem": "A patient with peptic ulcer bleeding is evaluated after endoscopic hemostasis. A $64$-year-old man, $6$ weeks after placement of a drug-eluting coronary stent, is on dual antiplatelet therapy that includes clopidogrel. He presented with melena, a drop in hemoglobin to $7.8$ g/dL, and endoscopy confirmed a bleeding duodenal ulcer treated with injection, thermal therapy, and clipping. The surgical team plans secondary prevention to reduce rebleeding risk. They debate whether to continue Proton Pump Inhibitors (PPIs) given concerns about Cytochrome P450 $2$C$19$ (CYP$2$C$19$)-mediated reduction in clopidogrel activation.\n\nStarting from fundamental principles of peptic ulcer pathophysiology and hemostasis, and separating local gastric luminal $pH$ effects from systemic hepatic drug metabolism, choose the statement that best justifies continuation of PPIs in this patient:\n\nA. Continue a PPI and, if possible, select an agent with low CYP$2$C$19$ inhibitory potential (for example, pantoprazole). Raising gastric $pH$ with a PPI reduces pepsin-mediated clot degradation and stabilizes platelet-fibrin hemostasis at the ulcer base, while clopidogrel activation occurs in the liver via CYP$2$C$19$ and is independent of gastric luminal $pH$.\n\nB. Discontinue PPIs because increasing gastric $pH$ diminishes clopidogrel absorption, thereby weakening its antiplatelet effect and increasing stent thrombosis risk.\n\nC. Maintain omeprazole but dose it $12$ hours apart from clopidogrel to avoid CYP$2$C$19$ inhibition; temporal separation preserves clopidogrel activation while still providing mucosal protection.\n\nD. Replace PPIs with a Histamine-$2$ Receptor Antagonist (H$2$RA) because H$2$RAs provide equivalent maintenance of gastric $pH>6$ without any interaction with clopidogrel.\n\nE. Use antacids after meals to transiently neutralize acid to $pH>4$, which is sufficient to prevent rebleeding and avoids any risk of systemic drug interaction with clopidogrel.",
            "solution": "The central task is to justify the continuation of Proton Pump Inhibitor (PPI) therapy in a patient at high risk for both ulcer rebleeding and coronary stent thrombosis. This requires a careful analysis of the distinct physiological and pharmacological processes involved.\n\n**Fundamental Principles**\n\n1.  **Pathophysiology of Ulcer Rebleeding:** Following initial hemostasis of a bleeding peptic ulcer, a platelet-fibrin clot forms at the site of the vascular breach. This clot is crucial for preventing rebleeding but is vulnerable to the aggressive luminal environment of the upper gastrointestinal tract. The primary threat to the clot is the proteolytic enzyme pepsin. Pepsinogen, secreted by chief cells in the stomach, is converted to its active form, pepsin, at a gastric luminal $pH  4$. Pepsin digests proteins, including the fibrin meshwork that stabilizes the clot. Therefore, preventing clot digestion requires suppression of peptic activity.\n\n2.  **Pharmacodynamics of PPIs (Local Gastric Effect):** PPIs irreversibly inhibit the H⁺/K⁺-ATPase (the proton pump) in gastric parietal cells, leading to profound and sustained suppression of acid secretion. By raising the intragastric $pH$ to levels consistently above $4$ and ideally above $6$, PPIs achieve two critical goals for hemostasis:\n    *   **Inhibition of Pepsin:** At $pH > 4$, the conversion of pepsinogen to pepsin is inhibited, and existing pepsin is irreversibly denatured. This removes the primary enzymatic threat to the clot.\n    *   **Stabilization of Platelet Aggregation:** Platelet function and aggregation are optimal at a neutral $pH$. An acidic environment impairs platelet aggregation. By maintaining a higher $pH$ (ideally $pH > 6$), PPIs create a more favorable environment for clot stabilization and maturation.\n    The clinical benefit of PPIs in reducing the risk of rebleeding, need for surgery, and mortality in patients with high-risk bleeding ulcers is well-established through numerous randomized controlled trials and meta-analyses.\n\n3.  **Pharmacology of Clopidogrel (Systemic Hepatic Effect):** Clopidogrel is a prodrug that requires biotransformation in the liver to become an active antiplatelet agent. This activation is a two-step process mediated by cytochrome P$450$ (CYP) enzymes. The first and rate-limiting step is predominantly carried out by the enzyme CYP$2$C$19$. The active metabolite then irreversibly binds to the P$2$Y$_{12}$ receptor on platelets, inhibiting platelet activation and aggregation.\n\n4.  **Drug-Drug Interaction (Systemic Hepatic Effect):** Certain PPIs, particularly omeprazole and its enantiomer esomeprazole, are known inhibitors of the CYP$2$C$19$ enzyme. By competing for this enzyme, they can reduce the metabolic activation of clopidogrel. This pharmacokinetic interaction leads to lower plasma levels of the active clopidogrel metabolite and diminished antiplatelet effect as measured by ex vivo platelet function assays. This has raised theoretical concerns about an increased risk of atherothrombotic events, such as stent thrombosis, in patients receiving both drugs. It is crucial to note that this interaction occurs systemically in the liver and is entirely independent of the local effects of PPIs on gastric $pH$. The absorption of clopidogrel itself is not considered to be $pH$-dependent.\n\n**Evaluation of the Patient Scenario**\n\nThe patient presents a classic clinical dilemma. He has two competing high-risk conditions:\n*   **High risk of ulcer rebleeding:** Recent presentation with melena, a significant drop in hemoglobin (Hb) to $7.8$ g/dL, endoscopic confirmation of a bleeding ulcer requiring hemostasis, and the continued need for dual antiplatelet therapy.\n*   **High risk of stent thrombosis:** Recent ($6$ weeks prior) placement of a drug-eluting stent, for which effective dual antiplatelet therapy is critical to prevent a life-threatening thrombotic event.\n\nThe consensus from major gastroenterological and cardiological society guidelines is that in patients with a recent major gastrointestinal bleed, the definite and immediate life-threatening risk of rebleeding outweighs the more controversial and less certain clinical risk of adverse cardiovascular events from the PPI-clopidogrel interaction. Therefore, PPI therapy is mandatory. The optimal strategy involves mitigating the potential interaction by selecting a PPI with weak or no CYP$2$C$19$ inhibition. Pantoprazole and rabeprazole are generally considered to have a lower inhibitory potential than omeprazole and esomeprazole.\n\n**Option-by-Option Analysis**\n\n**A. Continue a PPI and, if possible, select an agent with low CYP$2$C$19$ inhibitory potential (for example, pantoprazole). Raising gastric $pH$ with a PPI reduces pepsin-mediated clot degradation and stabilizes platelet-fibrin hemostasis at the ulcer base, while clopidogrel activation occurs in the liver via CYP$2$C$19$ and is independent of gastric luminal $pH$.**\nThis statement accurately synthesizes the core principles. It correctly identifies the necessity of PPI therapy to prevent rebleeding by raising gastric $pH$ and inhibiting pepsin. It correctly separates this local gastric effect from the systemic hepatic metabolism of clopidogrel. It proposes the standard, evidence-based risk-mitigation strategy of using a PPI with a lower potential for CYP$2$C$19$ inhibition, such as pantoprazole. This represents the best clinical judgment in this scenario.\n**Verdict: Correct.**\n\n**B. Discontinue PPIs because increasing gastric $pH$ diminishes clopidogrel absorption, thereby weakening its antiplatelet effect and increasing stent thrombosis risk.**\nThis statement is fundamentally flawed. The absorption of clopidogrel is not significantly affected by gastric $pH$. The drug interaction concern is metabolic (hepatic CYP$2$C$19$ inhibition), not absorptive. Furthermore, discontinuing PPIs in this high-risk patient would unacceptably increase the risk of a potentially fatal rebleeding event.\n**Verdict: Incorrect.**\n\n**C. Maintain omeprazole but dose it $12$ hours apart from clopidogrel to avoid CYP$2$C$19$ inhibition; temporal separation preserves clopidogrel activation while still providing mucosal protection.**\nThis statement proposes a strategy that has been shown to be ineffective. The inhibitory effect of omeprazole on CYP$2$C$19$ is not sufficiently transient to be avoided by separating the doses by $12$ hours. PPIs have a long duration of action, and some may act as mechanism-based inhibitors, meaning they irreversibly inactivate the enzyme. Full recovery of enzyme activity requires new enzyme synthesis, which takes longer than $12$ hours. Therefore, temporal separation does not adequately mitigate the interaction.\n**Verdict: Incorrect.**\n\n**D. Replace PPIs with a Histamine-$2$ Receptor Antagonist (H$2$RA) because H$2$RAs provide equivalent maintenance of gastric $pH6$ without any interaction with clopidogrel.**\nThis statement contains a critical error regarding therapeutic equivalency. Histamine-$2$ Receptor Antagonists ($H_2RAs$) are less potent acid suppressants than PPIs. They are not capable of providing the same degree of sustained elevation of intragastric $pH$, particularly to the target of $pH > 6$ that is optimal for clot stability. For preventing rebleeding from high-risk ulcers, PPIs have demonstrated clear superiority over $H_2RAs$. The inferior efficacy of $H_2RAs$ makes them an inappropriate choice in this acute, high-risk setting.\n**Verdict: Incorrect.**\n\n**E. Use antacids after meals to transiently neutralize acid to $pH4$, which is sufficient to prevent rebleeding and avoids any risk of systemic drug interaction with clopidogrel.**\nThis statement proposes a grossly inadequate therapy. Antacids provide only very brief, temporary acid neutralization. They cannot maintain the sustained increase in $pH$ necessary to prevent pepsin activity and stabilize the clot over the days to weeks required for ulcer healing. Relying on antacids for secondary prevention of bleeding from a high-risk duodenal ulcer would be a dangerous deviation from the standard of care.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}